The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy
Open accessAbstract
In postmenopausal women with hormone receptor-positive early-stage breast cancer, the use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical outcomes compared with tamoxifen therapy. Women receiving such endocrine therapy may experience treatment-related side effects that negatively affect health-related quality of life (QoL) and adherence to therapy. In published clinical trials and in clinical practice, adverse events (AEs) constitute the main reason for nonadherence to endocrine treatment. Serious AEs are sometimes resolved by switching to a different agent, whereas other side effects can often be managed to allow patients to remain on therapy without sacrificing QoL. Across all adjuvant endocrine trials, regardless of the treatment received, vasomotor symptoms such as hot flashes are the most common side effects. Other frequently reported side effects, such as vaginal discharge, vaginal dryness, dyspareunia, and arthralgia, vary in prevalence between tamoxifen and AIs. Here we provide an overview of reported AEs of adjuvant endocrine therapy, focusing on those that are amenable to pharmacologic or nonpharmacologic management without treatment discontinuation. Also highlighted are specific management strategies that may improve patient QoL and thereby optimize adherence to therapy, which in turn might improve patient outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and can compromise quality of life [17, 18].”
In the citing paper
“An observational linguistic study that analyzed doctor-patient communication around adjuvant hormonal therapy found that doctors tend to do monologues providing general information about adjuvant hormonal therapy, but do not spend enough time discussing with the patient about potential barriers and how the treatment may particularly impact them.41”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [41]
Citations
Cites
1 retracted
RETRACTED: Drug-induced lupus erythematosus
Sarzi‐Puttini, P., Atzeni, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Lubrano, E., Sarzi‐Puttini, P., et al. (2005) · Autoimmunity · doi:10.1080/08916930500285857 · Cited by 125
RetractedHowell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284 · cited 1×
“Conversely, the systemic estrogen deprivation that results from AI therapy in postmenopausal women can result in bone resorption and osteoporosis, with higher fracture rates [2, 4, 7].”
BackgroundBaum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Self-citationA Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The Breast International Group (BIG) 1-98 Collaborative Group (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,584
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,116 · cited 3×
“005), suggesting inhibition of endometrial proliferation by the AI [7].”
BackgroundMethodInfluentialWiner, E. P., Hudis, C. A., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R. D., Edge, S. B., Gralow, J. R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,026
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954 · cited 1×
“Loss of libido Better patient/physician communication Transdermal testosterone Shifren et al. [ 66 ]”
BackgroundJin, Y., Desta, Z., Stearns, V., Ward, B. A., Ho, H., Lee, K.-H., Skaar, T. C., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Research works printed but not linked: 4
- Taylor M, Rastelli A, Civitelli R et al (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, TX
- Thompson JN, Napoli N, Civitelli R et al (2006) Effects of dietary calcium vs. calcium supplements on estrogen metabolism and bone density. Osteoporos Int 17:S205 (abstract P696MO)
- Plourde P, Locker G, Hoctin-Boes G et al (2005) Arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk-benefit analysis. Poster presented at: 7th Annual Lynn Sage Breast Cancer Symposium; October 6–9 2005; Chicago, Illinois
- Mok K, Mireskandari S, Juraskova I et al (2006) OVER (Olive oil Vaginal Exercises and Replens) Come. Psycho-Oncology 15:S332 (abstract 778)
Cited by
Sorted by citations
Montazeri, A. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-32 · Cited by 773
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018
Mokhtari-Hesari, P., & Montazeri, A. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01591-x · Cited by 462
Mann, E., Smith, M. J., Hellier, J., Balabanovic, J. A., Hamed, H., Grunfeld, E. A., & Hunter, M. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70364-3 · Cited by 307
A Randomized Trial to Increase Physical Activity in Breast Cancer Survivors
Rogers, L. Q., Hopkins-Price, P. L., Vicari, S., Pamenter, R. W., Courneya, K. S., Markwell, S. J., Verhulst, S. J., Hoelzer, K. L., Naritoku, C., Jones, L., et al. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31818e0e1b · Cited by 220
Metadata
- Authors
- Cella, D., & Fallowfield, L. J.
- Affiliations
- Northwestern University (US)
- Brighton and Sussex Medical School (GB)
- Corresponding author
- Cella, David
- Venue
- Breast Cancer Research and Treatment
- Published
- 2007-09-18
- Volume
- 107
- Issue
- 2
- Pages
- 167-180
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2034100757
- Cited by
- 286
- References
- 83
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 16 · 2023: 22 · 2022: 20 · 2021: 17 · 2020: 14 · 2019: 16 · 2018: 15 · 2017: 19 · 2016: 17 · 2015: 15 · 2014: 9 · 2013: 14 · 2012: 17
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- breast cancer, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, treatment-related adverse events, medication adherence, health-related quality of life, vasomotor symptoms, hot flashes, vaginal dryness, dyspareunia, joint pain, adverse event management, hormone receptor-positive breast cancer
- MeSH terms
- Aromatase, Breast Neoplasms, Clinical Trials as Topic, Endocrine System, Female, Humans, Medical Oncology, Patient Compliance, Quality of Life, Surveys and Questionnaires, Tamoxifen, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
